Geode Capital Management
NTGN

Geode Capital Management’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Geode Capital Management’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-212,119
Closed -$559K – 4188
2020
Q1 		$559K Buy
212,119
+36,467
+21% +$59.8K ﹤0.01% 3246
2019
Q4 		$207K Buy
175,652
+51,327
+41% +$82K ﹤0.01% 3783
2019
Q3 		$213K Buy
124,325
+2,061
+2% +$6.27K ﹤0.01% 3742
2019
Q2 		$579K Buy
122,264
+15,928
+15% +$89.2K ﹤0.01% 3410
2019
Q1 		$686K Buy
106,336
+46,027
+76% +$241K ﹤0.01% 3306
2018
Q4 		$303K Buy
60,309
+33,741
+127% +$236K ﹤0.01% 3551
2018
Q3 		$226K Buy
+26,568
New +$294K ﹤0.01% 3733

Geode Capital Management's NTGN Position: Q2 2020 in Review

Geode Capital Management sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 212,119 shares — an estimated $559K sold.

Geode Capital Management first reported a position in NTGN in Q3 2018 and held it in 7 quarters. The position peaked at $686K in Q1 2019. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

  • Geode Capital Management reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Geode Capital Management sold 212,119 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $559K.
  • Geode Capital Management first reported a position in Neon Therapeutics, Inc. Common Stock in Q3 2018 and held it in 7 quarters.
  • Geode Capital Management's Neon Therapeutics, Inc. Common Stock position peaked at $686K in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Geode Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.